We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$396M
Cap. Flow %
32.65%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 6.25%
3 Industrials 0.98%
4 Consumer Discretionary 0.93%
5 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
76
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.04M 0.17%
398,541
-270,000
-40% -$1.5M
EOLS icon
77
Evolus
EOLS
$385M
$1.83M 0.15%
+150,000
New +$2.12M
ASMB icon
78
Assembly Biosciences
ASMB
$498M
$1.81M 0.15%
7,354
-2,646
-26% -$487K
IFRX icon
79
InflaRx
IFRX
$250M
$1.31M 0.11%
+330,000
New +$964K
CNCE
80
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.29M 0.11%
140,000
– –
MLNX
81
DELISTED
Mellanox Technologies, Ltd.
MLNX
$990K 0.08%
8,452
-68,423
-89% -$7.77M
VIRX
82
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$723K 0.06%
61,194
– –
BLCM
83
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$516K 0.04%
40,000
-35,000
-47% -$323K
LRMR icon
84
Larimar Therapeutics
LRMR
$397M
$386K 0.03%
+28,973
New +$277K
IMVT icon
85
Immunovant
IMVT
$7.93B
$317K 0.03%
+20,000
New +$224K
CLRB icon
86
Cellectar Biosciences
CLRB
$20.5M
$197K 0.02%
292
– –
ABUS icon
87
Arbutus Biopharma
ABUS
$857M
– –
-500,000
Closed -$763K
AKRO
88
DELISTED
Akero Therapeutics
AKRO
– –
-130,000
Closed -$2.96M
CHTR icon
89
Charter Communications
CHTR
$17.3B
– –
-6,000
Closed -$2.47M
CUE icon
90
Cue Biopharma
CUE
$113M
– –
-1,667
Closed -$422K
DK icon
91
Delek US
DK
$4.16B
– –
-50,000
Closed -$1.81M
GILD icon
92
Gilead Sciences
GILD
$162B
– –
-205,000
Closed -$13.3M
ITRN icon
93
Ituran Location and Control
ITRN
$1.09B
– –
-135,311
Closed -$3.35M
MRSN
94
DELISTED
Mersana Therapeutics
MRSN
– –
-8,000
Closed -$316K
NICE icon
95
Nice
NICE
$5.79B
– –
-57,193
Closed -$8.22M
STRO icon
96
Sutro Biopharma
STRO
$401M
– –
-42,259
Closed -$3.84M
URGN icon
97
UroGen Pharma
URGN
$1.86B
– –
-335,817
Closed -$8M
TECX
98
Tectonic Therapeutic
TECX
$529M
– –
-10,527
Closed -$1.78M
PHXM
99
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-11,784
Closed -$523K
RETA
100
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-63,269
Closed -$5.08M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management deployed $396M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 74% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Arqule Inc, an estimated $20.7M trimmed.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.